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HUWE1 Is a Molecular Link Controlling RAF-1 Activity Supported by
the Shoc2 Scaffold
Eun Ryoung Jang, Ping Shi, Jamal Bryant, Jing Chen, Vikas Dukhande, Matthew S. Gentry, HyeIn Jang, Myoungkun Jeoung,
Emilia Galperin
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA
Scaffold proteins play a critical role in controlling the activity of the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway.
Shoc2 is a leucine-rich repeat scaffold protein that acts as a positive modulator of ERK1/2 signaling. However, the precise mecha-
nism by which Shoc2 modulates the activity of the ERK1/2 pathway is unclear. Here we report the identification of the E3 ubiqui-
tin ligase HUWE1 as a binding partner and regulator of Shoc2 function. HUWE1mediates ubiquitination and, consequently, the
levels of Shoc2. Additionally, we show that both Shoc2 and HUWE1 are necessary to control the levels and ubiquitination of the
Shoc2 signaling partner, RAF-1. Depletion of HUWE1 abolishes RAF-1 ubiquitination, with corresponding changes in ERK1/2
pathway activity occurring. Our results indicate that the HUWE1-mediated ubiquitination of Shoc2 is the switch that regulates
the transition from an active to an inactive state of the RAF-1 kinase. Taken together, our results demonstrate that HUWE1 is a
novel player involved in regulating ERK1/2 signal transmission through the Shoc2 scaffold complex.
The multitiered extracellular signal-regulated kinase 1/2(ERK1/2) signaling pathway is a highly conserved signaling
cascade that initiates a diverse range of cellular responses (1). Scaf-
fold proteins play an essential role in the regulation of the ERK1/2
signaling network (2, 3). In addition to their main function in the
assembly of protein complexes, scaffolds of the ERK1/2 pathway
are thought to deliver signal specificity, regulate accessibility to
substrates, target signals to a specific cellular location, and deter-
mine the biological outputs of the ERK1/2 pathway (4–6). Despite
the important role of scaffolds in the biological activities of
ERK1/2 signals, the mechanisms by which scaffolds exert their
functions and the role for scaffolds in regulating the dynamics of
ERK1/2 signaling remain poorly understood (2, 6, 7).
The scaffold protein Shoc2, initially identified inCaenorhabdi-
tis elegans as SUR-8/SOC2, is a critical positive regulator of the
ERK1/2 signaling pathway that integrates the Ras andRAF-1 com-
ponents of the ERK1/2 pathway into a multiprotein complex (8,
9). Aberrant targeting of Shoc2 to the plasma membrane (PM) is
found in patients with Noonan-like syndrome with loose anagen
hair (NS/LAH) (10). Ablation of Shoc2 in mice causes embryonic
lethality due to severe heart defects, indicating that this leucine-
rich repeat (LRR) protein is critical for embryonic development
(11). Depletion of this protein in cells also has a striking effect on
ERK1/2 signaling, particularly evident under physiological condi-
tions of epidermal growth factor receptor (EGFR) activation (12,
13). Several recent studies have suggested that Shoc2 modulates
Ras-dependent RAF-1 activation through accelerating the associ-
ation and the dissociation of the Ras–RAF-1 complex, although
the mechanism(s) remains unclear (14, 15). We have previously
demonstrated that upon the activation of the ERK1/2 pathway
Shoc2 translocates from the cytosol to late endosomes (LEs), pos-
sibly as part of the spatiotemporal regulation of signaling through
the Ras-RAF module (13). Given the essential role of this scaf-
fold in modulating the ERK1/2 signal, it is important to under-
stand the mechanisms by which Shoc2 controls the ERK1/2
pathway activity.
Ubiquitination, alongwith phosphorylation, is one of the best-
studied regulatory posttranslational modifications (16). The bio-
logical processes of protein degradation, cargo trafficking, gene
transcription, and immune response are controlled through ubiq-
uitination (17–19). A growing body of evidence also suggests that
ubiquitination is a mechanism that contributes to the regulation
of the cellular signaling cascades and catalytic activities of signal-
ing proteins (20–22). Ubiquitination is a multistep process that
ultimately results in the attachment of ubiquitin (Ub) chains to
lysine residues within target proteins. This process involves enzy-
matic activities of a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and a ubiquitin ligase (E3). The speci-
ficity of ubiquitination is achieved by a large number of distinct E3
ligases that are responsible for highly specific substrate recogni-
tion (16).
In the current study, we have identified the E3 ubiquitin ligase
HUWE1 to be a new partner in the Shoc2–Ras–RAF-1 scaffold
complex. HUWE1 (also called ARF-BP or MULE) is a large E3
ligase and amember of the homologous to E6-AP carboxyl termi-
nus (HECT) domain-containing family of E3 ubiquitin ligases
that is implicated in the regulation of cell proliferation, apoptosis,
neural differentiation, and the DNA damage response (23–25). It
is mainly expressed in heart, placenta, and brain tissues. Elevated
levels of HUWE1 have been found in lung, breast, and colorectal
carcinomas, and HUWE1-mediated ubiquitination has been
linked to cancer by its ability to target substrates such as p53 and
c-Myc for degradation (26–31). Missense mutations and gross
duplications in HUWE1 have been reported in patients with X-
linked Turner-type mental retardation (32, 33). However, rela-
tively little is known about the mechanisms regulating HUWE1
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function and, in particular, its role in regulating the ERK1/2 cas-
cade.
We have determined that HUWE1 is the E3 ligase that modu-
lates ubiquitination of Shoc2.We also established that ubiquitina-
tion of Shoc2-associated RAF-1 is controlled by HUWE1 and that
Shoc2 depletion abrogates RAF-1 ubiquitination. A Shoc2 ubiq-
uitination-deficient mutant was utilized to examine how impair-
ments in Shoc2 ubiquitination affect its function as a positive
regulator of the ERK1/2 pathway. Diminished Shoc2 ubiquitina-
tion leads to impaired RAF-1 ubiquitination, increased ERK1/2
phosphorylation, and higher rates of cell proliferation. Our stud-
ies provide evidence that Shoc2 serves as a scaffold platform for
HUWE1. HUWE1 acts as the ERK1/2 signal tuning component in
the scaffold complex, thereby controlling the intensity of ERK1/2
signaling flow through Ras and RAF-1. Our studies also present a
distinct mechanism by which ubiquitination is utilized as a
negative-feedback mechanism to control the ability of the non-
catalytic scaffold Shoc2 to control the signaling activity of the
ERK1/2 pathway.
MATERIALS AND METHODS
Reagents and antibodies. Epidermal growth factor (EGF) was obtained
from BD Bioscience. Cycloheximide and MG132 were purchased from
Enzo;N-ethylmaleimide (NEM)was fromThermo Scientific/Pierce. Spe-
cific proteins were detected using primary antibodies to the following:
EGFR, the A isoform of RAF (A-RAF), RAF-1 (S338), the B isoform of
RAF (B-RAF), ERK1/2, phospho-ERK1/2,MEK1/2, andGAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) (Cell Signaling); Shoc2 (Protein-
tech); hemagglutinin (HA; SydLabs Inc.); tag red fluorescent protein
(tRFP; Evrogen); glutathione S-transferase (GST), M-Ras, RAF-1, and
phospho-MEK1/2 (Santa Cruz); HUWE1 (Bethyl Laboratories Inc.);
ubiquitin (Covance); PP1c (Millipore); and cyclinD1 (kindly provided by
Mark Evers).
Yeast two-hybrid screening assays. The full-length human Shoc2
cDNA (see Fig. 1A) was cloned into the lexA vector pB27 as an N-LexA-
Shoc2-C fusion and screened against a human embryo ventricle and heart
prey cDNA library. Yeast two-hybrid screens were performed by Hybri-
genics SA (Paris, France).
Expression plasmids. tRFP-tagged Shoc2 (Shoc2-tRFP) was de-
scribed previously (34, 35). The pLVTHM-Shoc2 constructs expressing
Shoc2 short hairpin RNA (shRNA) were described previously (13). Trun-
cated Shoc2-tRFP-taggedmutants were generated as described previously
for the full-length Shoc2 (13). The MRAS construct carrying 3 HA moi-
eties (3HA-MRAS) was purchased fromMissouri S&T cDNAResource
Center (www.cdna.org). The plasmid carrying yellow fluorescent protein
(YFP)-tagged RAF-1 (YFP–RAF-1) was kindly provided by Alexander
Sorkin (University of Pittsburgh). The plasmid carrying the HECT do-
main of HUWE1 (plasmid 25211) was obtained from Addgene. The plas-
mids carryingHA-tagged ubiquitin and ubiquitinmutants were provided
by M. S. Gentry (University of Kentucky). A mammalian GST expression
vectorwas provided byHainingZhu (University of Kentucky). Amaltose-
binding protein (MBP) expression vector for protein purification was
provided by Craig Vander Kooi (University of Kentucky). Full-length
HA-HUWE1 was provided by K. Helin (Biotech Research & Innovation
Centre, Denmark). To generate a plasmid expressing HA-HECT, a for-
ward primer containing an EcoRI site and a reverse primer containing a
BamHI site after the stop codon were used to amplify the human HECT
sequence by PCR. To generate a plasmid expressing Shoc2-MBP, a for-
ward primer containing a BamHI site and a reverse primer containing a
NotI site after the stop codon were used to amplify the human Shoc2
sequence by PCR. All constructs were verified by dideoxynucleotide se-
quencing.
Cell culture and DNA transfections. 293FT cells (Invitrogen), Cos1
cells (ATCC),HeLa cells (ATCC), and stable cell lines (derivatives of Cos1
and HeLa cells) were grown in Dulbecco modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS) supplemented with
sodium pyruvate, minimal essential medium with nonessential amino
acids (MEM-NEAA), penicillin, streptomycin, and L-glutamate (Invitro-
gen). T47D cells were grown in RPMI 1640 medium containing 10% FBS
supplemented with sodium pyruvate, MEM-NEAA, penicillin, strepto-
mycin, and L-glutamate (Invitrogen).
Transfections of DNA constructs were performed using the polyeth-
yleneimine (Neo Transduction Laboratories, Lexington, KY) or TransIT
(Mirus Bio LLC) reagent. Expression of tag RFP-fused proteins was con-
firmed by Western blotting, as described below. Stably expressing cell
lines were selected by growing the transfected cells in the presence of
puromycin (0.4 g/ml).
siRNA transfections. To silence protein expression by RNA interfer-
ence, cells were seeded in 12-well plates (at 50 to 60%confluencewith 1ml
ofDMEM-FBS perwell) at least 20 h before transfection. Small interfering
(siRNA) transfections were performed at 24- to 36-h intervals according
to the manufacturer’s recommendations, using Dharmafect reagent 2
(Thermo Fisher Scientific/Dharmacon). The siRNA sequence used to tar-
get the HUWE1 transcripts was as follows: 5=-GAGUUUGGAGUUUGU
GAAGTT-3= (36). The efficiency of the siRNA knockdown was validated
by Western blotting.
Real-time quantitative PCR (qPCR). Seventy-two hours after the
transfection of HUWE siRNA, total RNA was isolated from HeLa cells
using a PureZOL/Aurum total RNA isolation kit (Bio-Rad) according to
themanufacturer’s instructions. Aliquots containing equal amounts of RNA
were subjected to reverse transcription-PCR (RT-PCR) analysis. Quantita-
tive RT-PCR was performed using SoAdvanced SYBR green Supermix
and a Bio-RadCFXdetection system (Bio-Rad). Sequence-specific primer
sets for the Shoc2 gene were 5=-TGCAGTCCCTCCCAGCAGAGG-3=
and 5=-GCCGTAAATCAAGCATCCGCAGC-3=, and sequence-specific
primer sets for the hypoxanthine phosphoribosyltransferase 1 (HPRT1)
genewere 5=-GGCGGCTGCGACGAGCCCTCA-3= and 5=-CGCGCGGG
CTGACTGCTCAGG-3=. HPRT1 mRNA was used as a reference gene.
The relative amounts of RNAs were calculated using the comparative
threshold cycle method (37). The values for the samples were normalized
against those for the reference gene, and the results are presented as the
fold change in the amount of Shoc2 mRNA recovered from cells trans-
fectedwith nontargeting siRNA.The data represent themeans standard
deviations (SDs) from two independent experiments.
Immunoprecipitation andWestern blot analysis. The cells grown in
35-mm dishes were placed on ice and washed with calcium- and magne-
sium-free phosphate-buffered saline (PBS), and the proteins were solubi-
lized in 20mMHEPES (Sigma), pH 7.6, containing 10mMNaCl, 1.5mM
MgCl2, 1mMEDTA(Sigma), 1mMEGTA (Sigma), 0.5mMphenylmeth-
ylsulfonyl fluoride (Sigma), 10 g/ml of leupeptin (Roche), 10 g/ml of
aprotinin (Roche), 5g/ml of pepstatin A (Sigma), and 50 mM -glycer-
ophosphate (Sigma) (lysis buffer) for 15 min at 4°C (38). Lysates were
then centrifuged at 2,500  g for 15 min to remove insoluble material.
Lysates were incubated with appropriate antibodies for 2 h, and the im-
munocomplexes were precipitated using protein A- or G-Sepharose. Im-
munoprecipitates and aliquots of cell lysates were denatured in the sample
buffer at 95°C, resolved by electrophoresis, and probed by Western blot-
ting with various antibodies, followed by chemiluminescence detection.
Western blotting was done as described previously (39). Proteins
transferred from SDS-polyacrylamide gels to nitrocellulose membranes
were visualized using a ChemiDoc analysis system (Bio-Rad). Several ex-
posures were analyzed to determine the linear range of the chemilumines-
cence signals. Quantification was performed using the densitometry anal-
ysis mode of Image Lab software (Bio-Rad, Inc.).
Denaturing immunoprecipitation for in vivo ubiquitination assay.
Denaturing immunoprecipitation was performed as described previously
(40). Cells were lysed in denaturing buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 1% Triton, 1% SDS, 1 mM Na3VO4, 10 mM NaF, 5 mM NEM, 10
M MG132) and boiled for 10 min. Lysates were diluted 1:10 with the
Jang et al.
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same buffer without SDS and incubated with the appropriate antibody
overnight with rotation at 4°C. Protein G-agarose (GE Healthcare Life
Sciences) was added, and the beads-agarose were washed four times in
lysis buffer (without SDS). Proteins were eluted at 95°C in SDS loading
buffer, separated by SDS-PAGE, and transferred to nitrocellulose.
Interaction of recombinant proteins. GST- and MBP-tagged pro-
teins were affinity purified and stored in PBS containing 10% glycerol.
Equal aliquots of human HECT coupled to glutathione-Sepharose beads
were incubated with recombinant Shoc2-MBP at 4°C for 16 h. The beads
were washed 4 times with cell lysis buffer and eluted with 2 Laemmli
sample buffer.
RESULTS
Shoc2 interacts with HUWE1.Our earlier studies suggested that,
in addition to tethering and enforcing physical proximity between
Ras and RAF-1, the Shoc2 function extends to the coordination
and integration of positive and negative ERK1/2 feedback loops
(41). Thus, we set out to identify the proteins of the Shoc2 feed-
back loops and the mechanism that regulates Shoc2 function. We
performed a yeast two-hybrid screen using full-length Shoc2 as
bait. Noonan-like syndrome with loose anagen hair (NS/LAH)
patients that carry the Shoc2 S2G substitution are predisposed to
congenital heart defects; thus, we chose the human adult/fetal
heart library for screening (10). Twenty-one of the 128 clones
identified to be positive were the isolates of the previously known
Shoc2-interacting partner M-Ras (41, 42). Additionally, we iden-
tified 41 isolates of the E3 ligase HUWE1. HUWE1 is a large pro-
tein with a molecular mass of 482 kDa, and all of the isolates were
mapped and contained the C-terminal catalytic domain of
HUWE1, the HECT domain (amino acid residues 4161 to 4374)
(Fig. 1A). To confirm the Shoc2-HUWE1 interaction under more
physiological conditions, we ectopically expressed tRFP-tagged
Shoc2 (Shoc2-tRFP) (41) and the HA-tagged HECT domain of
HUWE1 (HA-HECT) in 293FT cells. HA-tagged M-Ras was used
as a positive control andHA-tagged laforin (HA-laforin), which is
not a HUWE1 substrate (41), was used as a negative control in
these experiments (Fig. 1B) (41). The HA-HECT domain but not
HA-laforin coprecipitated with Shoc2-tRFP (Fig. 1B). To ensure
that the interaction was not due to the tag, we also tested glutathi-
one S-transferase (GST)-fused Shoc2 (Shoc2-GST) with HA-
HECT. We found that Shoc2-GST coprecipitated with the HA-
HECT domain (Fig. 1C).
FIG 1 Shoc2 interacts with HUWE1. (A) Bait and prey regions of Shoc2 andHUWE1 in the yeast two-hybrid screening. (B) 293FT cells were cotransfected with
the HECT domain of HUWE1 (HA-HECT), HA–M-Ras, HA-laforin, and Shoc2-tRFP. HA-HECT was immunoprecipitated and analyzed by immunoblotting
using anti-HA and anti-Shoc2 antibodies. (C) 293FT cells were cotransfected with Shoc2-GST and HA-HECT. Shoc2 was immunoprecipitated using anti-GST
antibodies, and the immunoprecipitate was analyzed by immunoblotting using anti-HA and anti-Shoc2 antibodies. (D) Reciprocal coimmunoprecipitation of
endogenous Shoc2 and HUWE1. Shoc2 and HUWE1 antibodies were used to detect Shoc2 in HUWE1 immunoprecipitates, HUWE1 in Shoc2 immunopre-
cipitates, and Shoc2 and HUWE1 in total lysates of 293FT cells. (E) Recombinant Shoc2-MBP was mixed with GST-HECT coupled to glutathione-Sepharose
beads. The beads were washed, eluted, and detected byWestern blotting using anti-Shoc2 and anti-GST antibodies. The results in panels B to E are representative
of those from three independent experiments. IP, immunoprecipitation; IB, immunoblotting.
Ubiquitination of Shoc2 by HUWE1
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To further evaluate the Shoc2 and HUWE1 association, we
analyzed endogenous Shoc2 and HUWE1 proteins from 293FT
cells by immunoprecipitations. The immunoprecipitates were
then evaluated by immunoblotting with antibodies specific for
endogenous Shoc2 and HUWE1. Shoc2 readily precipitated with
endogenousHUWE1, andHUWE1precipitatedwith endogenous
Shoc2 (Fig. 1D). Moreover, we found that Shoc2 binds to the
catalytically inactive version ofHA-HECT (HA-HECT [C4341A])
as efficiently as its binds to wild-type (WT) HA-HECT (see Fig.
S1A in the supplemental material). To determine that Shoc2 and
HUWE1 are directly binding partners, we employed purified re-
combinant MBP-tagged full-length Shoc2 and the GST-tagged
HECT domain. We found that Shoc2 and HUWE1 interact in
vitro, demonstrating the direct binding of Shoc2 and HUWE1
(Fig. 1E; see also Fig. S1B and C in the supplemental material).
HUWE1 is a part of the Shoc2–Ras–RAF-1 signaling com-
plex. To determine whether HUWE1 is a part of the Shoc2–Ras–
RAF-1 signaling complex, we expressed and precipitated HA–M-
Ras from cells in which endogenous Shoc2 was reconstituted with
shRNA-insensitive Shoc2-tRFP (43). HA–M-Ras readily precipi-
tated endogenousHUWE1 and RAF-1 as well as Shoc2-tRFP (Fig.
2A). Similarly, we examined whether HUWE1 coprecipitates with
RAF-1. We pulled down GST-tagged RAF-1 from cells expressing
the full-length HA-tagged HUWE1 and detected a substantial
amount of HA-HUWE1 and endogenous Shoc2 precipitate with
GST–RAF-1 (Fig. 2B). Cumulatively, these results indicate that
HUWE1 is a novel interacting partner in the Shoc2–Ras–RAF-1
scaffold complex. Furthermore, HUWE1 catalytic activity is not
required for its interaction with Shoc2.
HUWE1 binds to the LRR12 to LRR14 region of Shoc2. To
better characterize the interaction between HUWE1 and Shoc2,
we utilized truncated forms of Shoc2 and mapped the domain of
Shoc2 that is required for binding to the HA-tagged HECT do-
main of HUWE1. Shoc2 is comprised of two functional domains:
an N-terminal domain that mediates Ras and RAF-1 binding and
a domain containing a core of 21 leucine-rich repeats (LRRs) (Fig.
3A) (41). We found that deletion of C-terminal LRRs 12 to 21 of
Shoc2 (12-C) abolished the Shoc2-HECT interaction (Fig. 3B,
lane 3), whereas deletion of the N-terminal region of Shoc2 to-
gether with LRRs 1 to 11 (N-11) had no effect on Shoc2-HECT
binding (Fig. 3B, lane 4).Deletion of only theN-terminal region of
Shoc2 (LRRs) had no effect on binding to the HECT domain of
HUWE1 (Fig. 3B, lane 5). To further define the interaction, addi-
tional truncation mutants with mutations in the C terminus of
Shoc2 were used to coimmunoprecipitate HECT (Fig. 3C and D).
A fragment of 71 residues that corresponds to LRRs 12 to 14 was
sufficient for HECT domain binding (Fig. 3E, lane 2). Altogether,
our data show that HUWE1 binds repeats 12 to 14 of the Shoc2
LRR domain. Repeats 12 to 14 are dispensable for the Shoc2–M-
Ras interaction (41). Therefore, the Shoc2 and HUWE1 associa-
tion is independent of Shoc2–M-Ras or RAF-1 binding.
HUWE1 mediates ubiquitination of Shoc2 and RAF-1.
HUWE1 is an E3 ubiquitin ligase that ubiquitinates multiple sig-
naling proteins (44–46). Therefore, we examined whether
HUWE1 catalyzes the ubiquitination of Shoc2 or its signaling
partner, RAF-1. While modification of RAF-1 by ubiquitin has
been reported (47–49), ubiquitination of Shoc2 has not been pre-
viously demonstrated. To determine whether Shoc2 undergoes
ubiquitination, we precipitated GST-Shoc2 from cells that were
lysed under denaturing conditions and examined Shoc2 ubiquiti-
nation using anti-Ub antibodies. The analysis revealed that Ub
exhibiting a molecular mass greater than250 kDa is associated
with Shoc2, suggesting that multiple ubiquitinmoieties are incor-
porated into Shoc2 (see Fig. S2A in the supplemental material).
Similar results were obtained when ubiquitination of GST-Shoc2
was examined in cells coexpressing HA-tagged ubiquitin (HA-
Ub). Shoc2-HA-Ub species also accumulated at the high molecu-
larmass (see Fig. S2B in the supplemental material). Interestingly,
treatment of cells with the proteasome inhibitorMG132 increased
the level of Shoc2 ubiquitination only moderately, and we did not
observed a substantial increase in Shoc2. Our findings of a mini-
mal change in Shoc2 ubiquitination in the presence of the protea-
some inhibitor imply that most of the ubiquitinated Shoc2 is not
an immediate target for the proteasome. To confirm that ubiqui-
tin was conjugated to Shoc2 and not to the Shoc2 binding partner
RAF-1, blots were reprobed with antibodies against RAF-1. We
did not detect RAF-1 in the Shoc2 immunoprecipitates under the
conditions of denaturing lysis (not shown).
FIG 2 Shoc2 and HUWE1 form a complex with M-Ras and RAF-1. (A) Cos1-SR cells were transfected with HA–M-Ras. HA–M-Ras was immunoprecipitated,
and precipitates were then analyzed by immunoblotting using anti-HUWE1, anti-RAF-1, and anti-tRFP antibodies. (B) 293FT cells were cotransfected with
GST–RAF-1 and HA-HUWE1. GST–RAF-1 was immunoprecipitated, and precipitates were then analyzed by immunoblotting. HUWE1 and Shoc2 were
detected in GST–RAF-1 immunoprecipitates and lysates using anti-HUWE1 and anti-Shoc2 antibodies.
Jang et al.
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To determine whether Shoc2 serves as a substrate for HEWE1
in vitro, we performed in vitro ubiquitination assays using recom-
binant, purified proteins. We generated 35S-labeled in vitro-tran-
scribed Shoc2 (see Fig. S2C in the supplemental material) along
with the HECT domain of HUWE1 purified from Escherichia coli.
The addition of recombinant Ub E1 (E1), GST-UbcH5 (E2), ATP,
and His6-Ub resulted in no detectable ubiquitination viaWestern
analysis. Similarly, the addition of either Shoc2 or HUWE1 to this
mixture yielded little to no ubiquitination. However, the addition
of the HUWE1 HECT domain and Shoc2 resulted in dramatic
Shoc2 ubiquitination (see Fig. S2D in the supplemental material).
To further probe the role of HUWE1 in the ubiquitination of
either Shoc2 or RAF-1, we silenced the expression of HUWE1
using a specific HUWE1 siRNA (36). Knockdown of HUWE1
dramatically reduced the ubiquitination of endogenous Shoc2
(Fig. 4A), GST-Shoc2 (Fig. 4B), and YFP–RAF-1 (Fig. 4C). We
also observed that HUWE1 knockdown led to an increase in
RAF-1 proteins levels, indicating that HUWE1may be involved in
the regulation of RAF-1 stability (Fig. 4C, lysate). Interestingly,
treatment of cells with the proteasome inhibitor MG132 signifi-
cantly increased the ubiquitination of RAF-1, suggesting that
ubiquitinated RAF-1 is a target for the proteasome (Fig. 4C, lanes
1 and 3). This result is addressed in detail below. Expression of
full-length HA-HUWE1 or the HA-HECT domain of HUWE1
induced the ubiquitination of Shoc2 (Fig. 4D and E) and RAF-1
(Fig. 4F and G). Conversely, overexpression of the catalytically
defective mutant with a mutation in the HA-HECT domain
(C4341A) (50) did not increase the ubiquitination of Shoc2 (Fig.
4D, lane 3) or RAF-1 (Fig. 4F, lane 3). Cumulatively, these results
indicate that HUWE1 is the E3 ligase that mediates the ubiquiti-
nation of both Shoc2 and RAF-1.
Shoc2 is essential for HUWE1-mediated ubiquitination of
RAF-1. Given that Shoc2 is a scaffold that tethers signaling pro-
teins in close proximity, we speculated that Shoc2 tethersHUWE1
to ubiquitinate RAF-1. Thus, we investigated whether the loss of
Shoc2 in cells affects HUWE1-mediated ubiquitination of RAF-1.
In these experiments, we utilized stable cells constitutively de-
pleted of Shoc2 (LV1) or depleted and then reconstituted with the
shRNA-insensitive Shoc2-tRFP (SR) (13, 35, 41). Cells expressing
nontargeting (NT) siRNA were utilized as an additional control
(41). As expected, HUWE1 knockdown induced a clear decrease
in RAF-1 ubiquitination in HeLa cells expressing Shoc2 (NT)
(Fig. 5, lanes 1 and 2). Conversely, we found that in cells lacking
Shoc2 (LV1), depletion of HUWE1 had no effect on already re-
FIG 3 Mapping the interacting domains of HUWE1 and Shoc2. (A) Schematic representation of the Shoc2 truncated mutants used in the assays whose results
are presented in panel B. (B) 293FT cells were cotransfected with HA-HECT and the Shoc2-tRFP truncated mutants depicted in panel A. HA was immunopre-
cipitated and analyzed by immunoblotting using anti-HA and anti-tRFP antibodies. (C) Schematic representation of Shoc2 truncatedmutants used in the assays
whose results are presented in panels D and E. (D and E) 293FT cells were cotransfected with HA-HECT and the Shoc2 truncated mutants depicted in panel C.
HA was immunoprecipitated and analyzed by immunoblotting using anti-HA, anti-tRFP, and anti-GST antibodies. The results in panels B, D, and E are
representative of those from three independent experiments.
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duced basal levels of RAF-1 ubiquitination (Fig. 5, lanes 3 and 4).
Reconstitution of endogenous Shoc2 with Shoc2-tRFP (SR) res-
cued the effect of HUWE1 depletion on the ubiquitination of
RAF-1 (Fig. 5, lanes 5 and 6). These results demonstrate that the
presence of Shoc2 is necessary forHUWE1-mediatedRAF-1 ubiq-
uitination. We again observed that in cells expressing Shoc2,
HUWE1 knockdown leads to an increased abundance of RAF-1,
suggesting that HUWE1 depletion may affect RAF-1 stability.
Reminiscent of our previous findings (13), depletion of Shoc2 also
led to an increase in the level of RAF-1. To demonstrate that the
FIG 4 HUWE1 regulates ubiquitination of Shoc2 and RAF-1. (A) Shoc2 was precipitated from HeLa cells using Shoc2 antibodies. Shoc2 ubiquitination was
detected with anti-UB antibodies. Immunoprecipitates and lysates were analyzed by immunoblotting using anti-HUWE1 and anti-Shoc2 antibodies. (B)
GST-Shoc2 was precipitated fromHeLa cells transfected with HA-Ub using glutathione-Sepharose. Shoc2 ubiquitination was detected with anti-HA antibodies.
Immunoprecipitates and lysateswere analyzed by immunoblottingwith anti-HUWE1 and anti-GST antibodies. (C)HeLa cells were transfectedwithYFP–RAF-1
and HA-Ub. Cells were treated with the proteasome inhibitor MG132 (10 M). YFP–RAF-1 was precipitated using anti-green fluorescent protein (anti-GFP)
antibodies that cross-react with YFP. RAF-1 ubiquitination was detected with anti-HA antibodies. Immunoprecipitates and lysates were analyzed by immuno-
blotting with anti-HUWE1 and anti-RAF-1 antibodies. (D) 293FT Shoc2-GST-expressing cells were cotransfected with WT HA-HECT or HA-HECT with the
C4341A (C/A) substitution. GST-Shoc2 was precipitated using glutathione-Sepharose, and Shoc2 ubiquitination was detected with anti-Ub antibodies. (E)
293FT Shoc2-GST-expressing cells were transfected with the full-length HA-HUWE1. GST-Shoc2 was precipitated using glutathione-Sepharose, and Shoc2
ubiquitination was detected with anti-Ub antibodies. (F) 293FT cells were transfected withWTHA-HECT, HA-HECT with the C4341A substitution, or empty
vector. RAF-1 was precipitated using anti-RAF-1 antibody, and RAF-1 ubiquitination was detected with anti-Ub antibodies. (G) 293FT cells were transfected
with the full-length HA-HUWE1. RAF-1 was precipitated using anti-RAF-1 antibody, and RAF-1 ubiquitination was detected with anti-Ub antibodies. The
results in each panel are representative of those from three independent experiments. Lanes MW, molecular weight markers (numbers to the left of the gels are
in thousands).
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involvement of HUWE1 in the ubiquitination of RAF-1 in the
presence of Shoc2 is a part of a general mechanism that controls
the function of the Shoc2 signaling module, we recapitulated our
findings in different cells (see Fig. S3 in the supplemental mate-
rial).
HUWE1 regulates Shoc2-dependent ERK1/2 phosphoryla-
tion. We next sought to determine whether HUWE1-mediated
Shoc2 and RAF-1 ubiquitination affects ERK1/2 activity. To de-
termine this, we examined ERK1/2 phosphorylation in response
to EGF stimulation in cells depleted of HUWE1. We found that
silencing of HUWE1 induced a clear increase in ERK1/2 phos-
phorylation in cells expressing Shoc2, with themaximum increase
being observed 7 min after the stimulation of cells with EGF (Fig.
6A, lanes 4 to 6; see also Fig. S4 in the supplemental material).
Silencing of HUWE1 in the Shoc2-depleted cells did not lead to a
significant change in already dramatically reduced ERK1/2 phos-
phorylation (Fig. 6A, lanes 10 to 12). These results indicate that
HUWE1 mediates ERK1/2 phosphorylation in the presence of
Shoc2. To confirm that HUWE1 regulates ERK1/2 phosphoryla-
tion in the context of the Shoc2 scaffold complex, we utilized
stable cells differentially expressing Shoc2 (Fig. 6B). As expected,
HUWE1 knockdown led to a significant increase in RAF-1 and
ERK1/2 phosphorylation after stimulation of cells with EGF for 7
min (Fig. 6B, lanes 3 and 4). Conversely, in cells depleted of Shoc2
(LV1), HUWE1 silencing had essentially no effect on the levels of
phospho-ERK1/2 (Fig. 6B, lanes 7 and 8). Constitutive expression
of Shoc2-tRFP rescued the effect of HUWE1 depletion on the
amplitude of ERK1/2 phosphorylation (Fig. 6B, lanes 11 and 12).
These data support the conclusion that HUWE1 is a part of the
mechanism that modulates ERK1/2 activity transmitted through
the Shoc2 scaffold complex.
HUWE1 regulates the stability of RAF-1. As mentioned ear-
lier, HUWE1 depletion led to an increase in Shoc2 and RAF-1
protein levels (Fig. 4 and 6). Therefore, we investigated whether
HUWE1 targets Shoc2 andRAF-1 for degradation. First, we tested
whether silencing of HUWE1 affected the levels of the B and A
isoforms of RAF (B-RAF andA-RAF, respectively), as well as those
of EGFR, MEK1/2, and the earlier reported Shoc2-interacting
partner PP1c in different cell types (Fig. 7A) (42). We found that
only Shoc2 and RAF-1 levels were dramatically increased when
HUWE1 was depleted.
We then determined that the dramatic increase in the protein
levels of RAF-1 upon depletion of HUWE1 was observed only in
cells expressing Shoc2 (NT and SR) (Fig. 7B, lanes 1, 2, 5, and 6).
Depletion of HUWE1 in cells in which Shoc2 was silenced (LV1)
had no significant effect on the already elevated levels of RAF-1
due to the loss of Shoc2 (Fig. 7B, lanes 3 and 4). This result indi-
cates that HUWE1 controls RAF-1 stability only when HUWE1 is
associated with Shoc2.
We next inhibited protein translation by incubating the cells
with cycloheximide and examined the stability of endogenous
Shoc2 and RAF-1 by immunoblotting. Although the Shoc2 levels
were increased after HUWE1 was knocked down, we could not
detect any changes in the stability of Shoc2 in HUWE1-depleted
cells (Fig. 7C and D). In contrast, HUWE1 silencing led to an
increased abundance and an increased half-life of RAF-1 (Fig. 7C
and E), indicating that HUWE1modulates the stability of RAF-1.
To test whether HUWE1 regulates the level of Shoc2 indirectly by
controlling its transcription, Shoc2mRNA levels were tested using
real-time PCR. We found that Shoc2 mRNA expression was not
affected by HUWE1 depletion (Fig. 7F).
We then hypothesized that HUWE1-catalyzed Shoc2 ubiquiti-
nation mediates a function other than controlling the stability of
Shoc2. To gain further insights into the role of Shoc2 ubiquitina-
tion, we determined the type of Shoc2-conjugated ubiquitin link-
ages. Specific types of ubiquitination can regulate protein func-
tion, trafficking, or stability (21, 51). While K11- and K48-linked
polyubiquitination targets substrates to the proteasome, K63-
ubiquitin linkages are utilized to modify protein function in a
proteasome-independentmanner (52–54). To determine the type
of ubiquitination, we took advantage of a series of Ub mutants
with lysines (K) mutated to arginines (R). We transfected Shoc2-
GST and HA-tagged WT Ub or Ub with a mutation at K11 only,
K48 only, or K63 only into cells. Robust ubiquitination of Shoc2
byWT, K48-mutated-only, and K63-mutated-only HA-ubiquitin
was observed (Fig. 8A). In contrast, Shoc2-GST was only weakly
ubiquitinated by the K11-mutated-only ubiquitin. Thus, we con-
cluded that K48- and K63-ubiquitin linkages are the predominant
linkages that covalently attached to Shoc2. These data suggest that
controlling Shoc2 stability is not the only role for Shoc2 ubiquiti-
nation.
FIG 5 HUWE1 regulates the ubiquitination of RAF-1 in a Shoc2-dependent
manner. HeLa-NT, HeLa-LV1, andHeLa-SR cells were transiently transfected
with HUWE1 siRNA. At 48 h posttransfection, the cells were treated with
MG132. RAF-1was precipitated using anti-RAF-1 antibodies. RAF-1 ubiquiti-
nation was detected with anti-Ub antibodies. The expression of HUWE1,
RAF-1, and Shoc2 was analyzed using specific antibodies. The results in each
panel are representative of those from three independent experiments. Num-
bers to the left of the gels are molecular weights (in thousands). NT, nontar-
geting siRNA; H, HUWE1 siRNA.
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We also tested whether ubiquitination of Shoc2 is stimu-
lated by activation of the EGFR-ERK1/2 pathway. We found
that Shoc2 is basally ubiquitinated, but its ubiquitination is
increased when cells are stimulated with EGF for 15 min (Fig.
8B, second lane). The increase in ubiquitination was then fol-
lowed by a reduction in Shoc2 ubiquitination, which was ob-
served within 30 min of cell stimulation with EGF (Fig. 8B,
third lane). Interestingly, the maximum in the ubiquitination
of Shoc2 corresponds to a decline in phosphorylation of
ERK1/2 (Fig. 6A). Thus, EGF-induced activation of the ERK1/2
pathway appears to stimulate the capacity of HUWE1 to cata-
lyze the reversible ubiquitination of Shoc2. Our findings that
HUWE1 knockdown has very little effect on Shoc2 stability, as
well as our findings that the polyubiquitin chains that formed
on Shoc2 include K63-linked chains, a modification that gen-
erally does not target a substrate protein for proteasomal deg-
radation, agree with our hypothesis that HUWE1-mediated
Shoc2 ubiquitination has a role in addition to controlling
Shoc2 stability.
Ubiquitin-conjugated sites of Shoc2.As an approach to assess
the functional consequences ofHUWE1-mediated ubiquitination
of Shoc2, we mapped the lysine residues in Shoc2 that are modi-
fied by ubiquitin conjugation. Shoc2-FLAGwas precipitated from
cells using anti-FLAG antibodies and stringently washed to mini-
mize coprecipitation with other proteins. Immunoprecipitated
Shoc2-FLAG was separated by SDS-PAGE and visualized by
SYPRO Ruby protein gel stain (not shown). In order to analyze
ubiquitinated Shoc2 by mass spectrometry (MS), the gel regions
containing ubiquitin-modified Shoc2 protein were excised, di-
gested with trypsin, and analyzed by liquid chromatography-tan-
demMS (LC-MS/MS) (55, 56). Shoc2 was the predominant pro-
tein identified in these samples.Moreover, no other ubiquitinated
proteins were identified in these samples (not shown). A database
search using parameters allowing an additional mass of 114.1 Da,
corresponding to the ubiquitin remnant on lysine residues, iden-
tified eight distinct ubiquitination sites on Shoc2 at lysines 169,
170, 216, 228, 369, 439, 475, and 542 (Fig. 9A). Representative
spectra that demonstrate ubiquitination at Lys 369 are shown in
FIG 6 HUWE1-mediated ubiquitination is required to modulate the ERK1/2 pathway. (A) HeLa cells were depleted of HUWE1, Shoc2, or both by siRNA. At
48 h posttransfection, the cells were serum starved for 16 h and stimulated with EGF (10 ng/ml) for 7 or 15 min. The expression of the indicated proteins was
analyzed using specific antibodies. Multiple blots from the experiments whose results are exemplified in panel A were analyzed. Bars represent the mean values SDs
(n  3) for phosphorylated ERK1/2 (pERK1/2; 7 min of EGF treatment) normalized to the value for GAPDH in arbitrary units (phosphorylated ERK1/2/
GAPDH). (B) Cos1 cells stably depleted of Shoc2 (Cos-LV1) were transiently transfected with HUWE1 siRNA. In Cos-SR cells, Shoc2 was rescued with
Shoc2-tRFP. At 48 h posttransfection, the cells were serum starved for 16 h and stimulated with EGF (0.2 ng/ml) for 7 min. The expression of the indicated
proteinswas analyzed using specific antibodies.Multiple blots from the experiments forwhich the results are exemplified in panel Bwere analyzed. Bars represent
the mean values SDs (n 3) for phosphorylated ERK1/2 (7 min of EGF treatment) normalized to the value for GAPDH in arbitrary units (phosphorylated
ERK1/2/GAPDH). The results in each panel are representative of those from three independent experiments. *, a proteolytic fragment of Shoc2-tRFP that is often
detected by immunoblotting in cells expressing full-length Shoc2-tRFP. NT, nontargeting siRNA; tERK1/2, total ERK1/2; H, HUWE1 siRNA.
Jang et al.
3586 mcb.asm.org Molecular and Cellular Biology
 o
n
 D
ecem
ber 8, 2015 by UNIV O
F KENTUCKY
http://m
cb.asm
.org/
D
ow
nloaded from
 
Fig. S5A in the supplemental material. In each case, manual vali-
dation independently confirmed the ubiquitination site assign-
ment.
Sequence analysis revealed that all identified ubiquitination sites
map to the LRR region of Shoc2. Using a previously reportedmodel
of Shoc2,we found that the eight lysines are clustered into twogroups
at the N and C termini of the Shoc2 solenoid (Fig. 9B). To examine
the effects of Shoc2 ubiquitination on its function, each of the eight
lysines (K) of Shoc2 was replaced with arginines (R), to minimally
perturb the structure but prevent ubiquitination of the mutant pro-
teins. Single andmultiple (nKR)pointmutationswere generated and
expressed in293FTcells.Westernblot analysis revealed that ubiquiti-
nationof the7KRmutantwas reducedby	70%to80%compared to
that of WT Shoc2 (Fig. 9C). Despite multiple Lys¡ Arg mutations,
the extent of Shoc2 binding to the HECT domain of HUWE1, as
well as to M-Ras and RAF-1, was essentially similar to that of WT
Shoc2 (Fig. 9D; see also Fig. S5B in the supplemental material).
The cellular distribution as well as the half-life of the Shoc2(7KR)-
YFPmutant was largely similar to that ofWT Shoc2-YFP (see Fig.
S5C and D in the supplemental material). These data suggested
that multiple lysine-to-arginine substitutions had a direct effect
on ubiquitination but did not result in an unfolded protein, nor
did it affect the Shoc2 capacity to assemble the scaffold complex or
the cellular distribution.
HUWE1 regulates EGFR/RAF-1-induced cell proliferation.
To determine how HUWE1-mediated Shoc2 ubiquitination reg-
ulates the activity of the ERK1/2 pathway, we generated HeLa and
Cos1 cells in which endogenous Shoc2 was depleted and reconsti-
FIG 7 HUWE1 regulates the stability of RAF-1. (A) 293FT, Cos1, or HeLa cells were transiently transfected with HUWE1 siRNA. At 48 h after transfection, cells
were harvested for immunoblotting. The expression of Shoc2,HUWE1, B-RAF, A-RAF, RAF-1, EGFR,MEK1/2, PP1c, andGAPDHwas analyzed. (B) T47D cells
stably depleted of Shoc2 (T47D-LV1) were transiently transfected with HUWE1 siRNA. In T47D-SR cells, Shoc2 was rescued with Shoc2-tRFP. At 48 h after
transfection, cells were harvested for immunoblotting. The expression of Shoc2, HUWE1, RAF-1, and GAPDH was analyzed. (C) 293FT cells were transfected
with HUWE1 siRNA and subsequently treated with cycloheximide (CHX). Cell lysates were analyzed for HUWE1, Shoc2, RAF-1, cyclin D1, and GAPDH
expression using specific antibodies. (D) Graph showing the relative amount of Shoc2 that remained in cells following cycloheximide treatment. The proteins in
the immunoblots shown in panel Cwere quantified by normalizing the amounts of total Shoc2 to the amount ofGAPDH. (E)Graph showing the relative amount
of RAF-1 that remained in cells following cycloheximide treatment. The proteins in the immunoblots shown in panel C were quantified by normalizing the
amounts of total RAF-1 to the amount of GAPDH. (F) Total RNA was extracted from HeLa cells transfected with either NT siRNA (siNT) or an siRNA duplex
targeting HUWE1 (siHUWE1), and quantitative RT-PCR was performed using Shoc2-specific primers. The data are presented as the fold change of the Shoc2
mRNA levels in cells transfected with NT siRNA versus the Shoc2mRNA levels in cells transfected withHUWE1 siRNA (mean SD, n 2). HPRT1 is a control
mRNA.
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tuted with either shRNA-resistant WT Shoc2-YFP (HeLa-SY-
WT) or the Shoc2 7KR mutant-YFP (HeLa-SY-7KR) (13). In or-
der to prevent clonal variations due to the different sites of viral
genome incorporation in the following experiments, we utilized
pooled populations of cells. We examined the ubiquitination of
RAF-1 in cells expressing either WT Shoc2 or the Shoc2 7KRmu-
tant. Immunoprecipitation experiments showed that ubiquitina-
tion of RAF-1 was significantly lower in cells expressing the Shoc2
7KR mutant than in cells expressing WT Shoc2 (Fig. 10A). We
then tested whether decreased RAF-1 ubiquitination affects
RAF-1 phosphorylation and, subsequently, that of the kinases
MEK1/2 and ERK1/2. We found that the amplitude of RAF-1
phosphorylation at Ser338 as well as the phosphorylation of
MEK1/2 and ERK1/2 was higher in cells expressing the Shoc2 7KR
mutant than in cells expressing WT Shoc2 when stimulated with
EGF (Fig. 10B). We also observed that depletion of HUWE1 in
cells expressing the Shoc2 7KR mutant did not affect the already
increased ERK1/2 activity (see Fig. S6A in the supplemental ma-
terial). Similarly, when Cos1-SY-WT or Cos1-SY-7KR cells were
used, we observed increased ERK1/2 and RAF-1 phosphorylation
(see Fig. S6B in the supplemental material). These findings indi-
cate that reduced Shoc2 ubiquitination leads to abridged RAF-1
ubiquitination, followed by an increased amplitude of ERK1/2
phosphorylation.
It has been reported that overexpression of wild-type RAF-1
does not confer a proliferative advantage to cells (57). Similarly,
we also observed that overexpression of RAF-1 does not lead to an
increased ERK1/2 phosphorylation (see Fig. S6C in the supple-
mental material), yet hyperactivation of RAF-1 up to a certain
threshold was reported to induce the cell cycle and cell prolifera-
tion (58–60). Thus, we examined whether increased ERK1/2
phosphorylation in cells expressing the ubiquitin-deficient Shoc2
7KR mutant induces cell proliferation. We compared the growth
rates of cells expressing the Shoc2 WT and Shoc2 7KR mutant-
YFP and found that the rates of growth of Shoc2 7KR-YFP-ex-
pressing cells were markedly increased compared with those of
control cells (cells with the Shoc2 WT) (Fig. 10C and D; see also
Fig. S6D and E in the supplemental material). As the obtained
results were not due to the changes inMEK1/2 and ERK1/2 levels,
it suggested that increased proliferation is due to increased RAF-1
activation and the reduced ubiquitination of Shoc2.
DISCUSSION
The scaffold protein Shoc2 was shown to accelerate ERK1/2 activ-
ity by bringing several signaling proteins in close proximity: H-,
N-, K- andM-Ras, RAF-1, PP1c, and the recently identifiedmem-
ber of the LAP protein family SCRIB (8, 12, 42, 61).We previously
showed that, in addition to its function as an ERK1/2 pathway
signaling accelerator, Shoc2 integrates a negative ERK1/2 feed-
back loop that inhibits ERK1/2 signals. However, themechanisms
of these events have not been determined (41). In this study, we
identified the E3 ubiquitin ligase HUWE1 to be an integral com-
ponent of the Shoc2–Ras–RAF-1 scaffold complex. Our results
demonstrate that binding of HUWE1 to Shoc2 provides a molec-
ular mechanism for inhibition of the ERK1/2 signaling activity.
HUWE1 is a part of the Shoc2–Ras–RAF-1 signaling com-
plex. Several lines of evidence indicate that HUWE1 is a binding
partner in the Shoc2 scaffold complex: (i) a pool of endogenous
Shoc2 is found in the same molecular complex with HUWE1, (ii)
HUWE1 is found in the samemolecular complex withM-Ras and
RAF-1, (iii) the HECT domain of HUWE1 interacts with Shoc2 in
vitro, in the absence of other components of the complex, and (iv)
repeats 12 to 14 of Shoc2’s LRR domain are sufficient for HUWE1
binding to Shoc2 (Fig. 1 to 3). Although it is unusual for HECT
domain E3 ligases to interact with their partners through the cat-
alytic domain, it is not unprecedented, particularly for HUWE1.
An essential component of the DNA polymerase CDC6 is modu-
lated by HUWE1 and is also recognized through the HECT do-
main of HUWE1 (36).
HUWE1 is the E3 ligase for both Shoc2 and RAF-1. Our re-
sults show that the Shoc2 interaction with HUWE1 results in
ubiquitination of Shoc2. We found that HUWE1-polyubiquiti-
nated lysine residues are within Shoc2’s LRR domain. Consistent
with our findings thatHUWE1 promotedK63 polyubiquitination
FIG 8 Ubiquitination of Shoc2 in cells stimulated with EGF. (A) 293FT cells were transiently cotransfected with GST-Shoc2 and HA-taggedWTUb or mutants
with ubiquitinmutations at K11 only, K48 only, or K63 only. Shoc2 was precipitated using anti-GST antibodies, followed by immunoblotting with the indicated
antibodies. (B) HeLa cells were transfected with GST-Shoc2 andHA-Ub. At 48 h posttransfection, the cells were serum starved for 16 h and stimulated with EGF
(10 ng/ml) for 15 and 30min. GST-Shoc2 was precipitated using glutathione-Sepharose. Shoc2 ubiquitination was detected with HA antibodies. The expression
of Shoc2 was analyzed using Shoc2-specific antibodies. The mean amount of Ub normalized to the total amount of Shoc2 ubiquitination at 0 min SD from
three experiments is presented on the graph. The results in each panel are representative of those from three independent experiments. Numbers to the left of the
gels are molecular weights (in thousands).
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FIG 9 Identification of multiple ubiquitination sites in the LRR domain of Shoc2 by LC-MS/MS. (A) FLAG-Shoc2 was precipitated from transiently
transfected 293FT cells. Eight ubiquitination sites were identified within the LRR domain. Each peptide was characterized by a GG-modified lysine, which
caused them to bear an additional mass of 114.1 Da. Peptides matching the MS/MS spectra were accepted only if their masses varied by less than 10 ppm
from the expected monoisotopic mass of the parent ion. (B) Ub-modified lysines were mapped on a previously reported modeled structure of the Shoc2
LRR domain. (C) Lysines depicted in panel A were mutated to arginines (5KR, 6KR, 7KR, and 8KR). The WT and mutants of Shoc2 were transiently
coexpressed with HA-Ub in 293FT cells. Shoc2 immunoprecipitates were probed with HA and Shoc2 antibodies. The mean amount of Ub (%) normalized
to the total amount of WT Shoc2 SD from three experiments is presented on the graph. (D) 293FT cells were cotransfected with Shoc2 WT-YFP, Shoc2
7KR mutant-YFP, and HA-HECT. The HECT domain was detected in WT Shoc2-YFP and Shoc2 7KR mutant-YFP immunoprecipitates and lysates from
transfected 293FT cells. Immunoprecipitates were analyzed by immunoblotting using HA and Shoc2 antibodies. Numbers to the left of the gels are
molecular weights (in thousands).
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of Shoc2, HUWE1 inhibited the ability of Shoc2 to accelerate
ERK1/2 phosphorylation. Though HUWE1 has been shown to
synthesize K48 chains on several of its substrates, including p53,
ARF, Mcl-1, and N-Myc (46, 62, 63), it also preferentially assem-
bles K63 chains on c-Myc (52) and on its recently identified sub-
strate Dvl (64). In both cases, HUWE1-induced ubiquitination
was shown to be a part of a negative-feedback loop. We do not
have an explanation for the K48-linked ubiquitination or for the
increased abundance of Shoc2 in HUWE1-depleted cells. An at-
tractive hypothesis is that HUWE1 controls the turnover of a spe-
cific pool of Shoc2, conceivably, the spatially restricted pool of
Shoc2 that is found in endosomes (13). Hence, changes in the
degradation rates of the Shoc2, when analyzed using a total cell
lysate, may be masked by the total Shoc2, thereby preventing de-
tection of the differences in the rates of degradation of specific
Shoc2 pools.
In this study, we also show thatHUWE1 is a E3 ubiquitin ligase
for RAF-1. Importantly, Shoc2 is required to observe the effects of
HUWE1 silencing on the stability and phosphorylation of RAF-1,
thus placing Shoc2 in the center of aHUWE1-dependent feedback
loop (Fig. 5 and 6). The silencing of Shoc2 itself led to an increase
in RAF-1, thus supporting the notion that HUWE1 controls
RAF-1 stability when it is in complex with Shoc2. The increase in
RAF-1 and ERK1/2 phosphorylation that was detected in our ex-
periments cannot be simply attributed to the stabilization of either
Shoc2 or RAF-1 proteins (41, 61) (see Fig. S6 in the supplemental
material). Therefore, our findings strongly suggest that, in the
context of the Shoc2–RAF-1 scaffolding complex, HUWE1 regu-
lates two events: (i) the amplitude of signal transmission in the
Shoc2 module and (ii) the stability of both partners. Moreover,
our data further support the notion that K63 polyubiquitination
by HUWE1 is an important mechanism by which HUWE1 con-
trols the signaling activities of proteins in mammalian cells.
Functional implications of HUWE1-mediated regulation of
Shoc2.We found that ablation of Shoc2 ubiquitination alters the
amplitude of RAF-1 and ERK1/2 phosphorylation (Fig. 10; see
FIG 10 Diminished Shoc2 ubiquitination alters the ubiquitination of RAF-1 and ERK1/2 signaling. (A) RAF-1 was immunoprecipitated fromHeLa cells stably
expressing eitherWT Shoc2-YFP or Shoc2 7KRmutant-YFP. The ubiquitination of RAF-1 was detected with anti-Ub antibodies. Numbers to the left of the gels
aremolecular weights (in thousands). (B) HeLa-SY cells stably expressing eitherWT Shoc2-YFP or Shoc2 7KRmutant-YFP were serum starved and treated with
10 ng/ml of EGF for the indicated times. The cell lysates were probed for phosphorylated RAF-1 (S338), phosphorylated MEK1/2, phosphorylated ERK1/2,
RAF-1, and GAPDH. (C) Equal numbers of HeLa-SY cells constitutively expressing either WT Shoc2-YFP or the Shoc2 7KR mutant-YFP were plated onto 24
wells, and the numbers were counted 24, 48, and 72 h after seeding. The graph depicts the mean number from triplicate experiments SD. (D) The viability of
HeLa-SY cells constitutively expressing either WT Shoc2-YFP or Shoc2 7KR mutant-YFP was measured using a CellTiter 96 AQueous One solution cell
proliferation assay. The graph depicts the mean number from triplicate experiments  SD. The results in each panel are representative of those from three
independent experiments. OD, optical density.
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also Fig. S6 in the supplementalmaterial). Cells expressing a Shoc2
ubiquitination-defective mutant (7KR) showed higher rate of
proliferation, likely due to changes in the activity of the ERK1/2
pathway. Thus, our findings place HUWE1 at the negative-feed-
back loop regulating the ERK1/2 pathway activity.
The results of this study indicate that, in addition to tethering
of Ras and RAF-1 to accelerate ERK1/2 activity, Shoc2 also allows
HUWE1 to fine-tune its capacity to accelerate signals transmitted
through its complex. By coupling Ras–RAF-1 phosphorylation
signals with HUWE1-induced Shoc2 ubiquitination, the dynamic
range of RAF-1 activity can be fine-tuned within normal param-
eters to fit a given physiological situation. Thus, ubiquitin modi-
fication of a noncatalytic Shoc2 scaffold may play an active role in
controlling ERK1/2 activity. How the ubiquitin systemmay func-
tion to control Shoc2 complex assembly, stability, and, ultimately,
the degradation of molecules in the complex is yet to be defined.
Also, whether RAF-1 ubiquitination is a cause or a consequence of
RAF-1 dissociation from the complex and ultimate degradation is
not currently known. It is tempting to speculate that ubiquitina-
tion is the posttranslational modification that impacts Shoc2
function allosterically by eliciting its conformational change.
Changes in Shoc2 conformation will be followed by alterations in
the accessibility of RAF-1 to HUWE1. Future studies of ubiquiti-
nated/deubiquitinated Shoc2 complexes will resolve the basis for
this hypothesis. It is also possible, if not likely, that Shoc2 provides
a binding surface for additional partners and allows signaling se-
lectivity. It may form distinct scaffolding complexes in different
tissues or under different physiological conditions. Such complex-
ity predicts that alterations in Shoc2 structure/function may have
important effects on cell signaling and behavior. Not surprisingly,
the S2G substitution in Shoc2 caused congenital NS/LAH syn-
drome with pathological conditions ranging from distinctive
craniofacial dysmorphisms, a wide spectrum of congenital heart
defects, short stature, and variable neurocognitive impairments to
brain anomalies and myelofibrosis (65, 66).
Based on our results, we propose the following model with
regard to what is currently understood of the regulation of the
ERK1/2 pathway through the Shoc2 module (Fig. 11A). In this
model, in the context of a Shoc2 scaffolding platform, HUWE1
has a dual role andmodifies the ubiquitination of both Shoc2 and
RAF-1. Activation of the ERK1/2 pathway induces HUWE1-me-
diated ubiquitination of Shoc2, which is followed by the subse-
quent ubiquitination of RAF-1. Ubiquitination of Shoc2 and
RAF-1 leads to changes in the dynamics of ERK1/2 signaling and
stabilization of both proteins (Fig. 5 to 10). It will be important to
determine whether the Shoc2 scaffold is able to recruit a deubiq-
uitinating enzyme (DUB) and what E2 ubiquitin ligase is in the
complex. Conceivably, impairments in this mechanism will allow
an unrestricted number of functional scaffold complexes and sub-
sequent uncontrolled ERK1/2 signaling, leading to changes in cel-
lular behavior (i.e., increased cell proliferation) (Fig. 10). It would
be interesting to examine our model in the presence and absence
of constitutively active Ras/RAF-1 and determine how RAF-1 ac-
tivity changes with expression of ligase-defective HUWE1. Fur-
ther deciphering of the composition, dynamics, and function of
the HUWE1–Shoc2–RAF-1 complex will strengthen our under-
standing of the mechanisms that are extensively targeted by ther-
apeutics.
The implications of the HUWE1-mediated ubiquitination for
RAF-1/B-RAF dimerization and propagation of kinase activity
may be directly relevant to the clinical application of B-RAF in-
hibitors. An ability to switch between the activated/deactivated
statuses of RAF-1 in the Shoc2 complex would allow additional
fine-tuned control of the ERK1/2 pathway and may present an
opportunity to enhance the effectiveness of clinically relevant
B-RAF inhibitors. Further studies of this complex will also pro-
vide important insights into understanding of normal ERK1/2
signaling.
To summarize, our studies are the first to characterize the
ubiquitination of Shoc2, identify HUWE1 as a part of the ERK1/2
signaling, and provide insights into the novel mechanism modu-
lating ERK1/2 activity through controlling the signaling scaffold.
FIG 11 Model recapitulating the role played by HUWE1 in regulating Shoc2-supported ERK1/2 activity. (A) Shoc2 incorporates the E3 ligase HUWE1 into the
Ras and RAF-1 signaling complex. HUWE1-mediated ubiquitination of Shoc2 is necessary for the ubiquitination of RAF-1 and fine-tuning of RAF-1 activity
and/or its levels in the complex. The identities of the deubiquitinating enzyme (DUB) and the E2 ubiquitin ligase (E2) allowing transient ubiquitination of Shoc2
remain to be determined. (B) The absence of HUWE1 impedes mechanisms modulating the activity of the ERK1/2 pathway.
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